http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#Head
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#assertion
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#provenance
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#pubinfo
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#assertion
http://purl.obolibrary.org/obo/DOID_9477
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_9477
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB09075
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#association
http://www.w3.org/2000/01/rdf-schema#label
savaysa is a factor xa inhibitor indicated to reduce the risk of stroke and systemic embolism se in patients with nonvalvular atrial fibrillation nvaf 1 1 limitation of use for nvaf savaysa should not be used in patients with creatinine clearance crcl 95 ml min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied 6 mg 1 1 savaysa is indicated for the treatment of deep vein thrombosis dvt and pulmonary embolism pe following 5 to 1 days of initial therapy with a parenteral anticoagulant 1 2 savaysa is indicated to reduce the risk of stroke and systemic embolism se in patients with nonvalvular atrial fibrillation nvaf limitation of use for nvaf savaysa should not be used in patients with crcl 95 ml min because of an increased risk of ischemic stroke compared to warfarin see dosage and administr ation 2 1 warnings and precautions 5 1 clinical studies 14 1 savaysa is indicated for the treatment of deep vein thrombosis dvt and pulmonary embolism pe following 5 to 1 days of initial therapy with a parenteral anticoagulant
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB09075
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#provenance
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#pubinfo
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#sig
http://purl.org/nanopub/x/hasSignature
C88vhWrH8UxGbJwQ4mgedWcZXLu7YzDDfg24doYBbNFjR6j2bRyT+3Bk7LSuwdh/A67R9r7OFHLO9+M7sDOoAa5y2U2RIUNfKMmnpLFR1nQurqhtwtgqgvYMBs+n+A6XBI+SBc3vR4dKVCCmn3S7Xme3jEJzE3f1Mv3T9oykF/Y=
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI
http://purl.org/dc/terms/created
2021-07-03T14:45:03.647+02:00
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAiBtamq8tRkmne2X9GkJ2YHp-pgsAZQOtRKAcLY15EhI
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs